Infectious Disease > > Flu & & URI– Relative advantage was modest, however might offer considerable public health advantage
by Katherine Kahn, Staff Writer, MedPage Today December 13, 2023
A high-dose recombinant influenza vaccine (Flublok Quadrivalent) was more protective than an egg-based standard-dose influenza vaccine in grownups, according to outcomes of a cluster-randomized, observational research study.
Amongst grownups ages 50 to 64, the high-dose vaccine was 15.3% more efficient in avoiding influenza than the standard-dose vaccine (95% CI 5.9-23.8, P=0.002) and 15.7% more efficient versus influenza A (95% CI 6.0-24.5, P=0.002), reported Nicola Klein, MD, PhD, from the Kaiser Permanente Vaccine Study Center in Oakland, California, and coworkers in the New England Journal of Medicine
The relative advantage of the high-dose vaccine appears to be modest, “lowering advancement influenza cases by 15% would supply a significant public health advantage, particularly throughout more serious influenza seasons,” Klein informed MedPage Today in an e-mail.
Georges Benjamin, MD, executive director of the American Public Health Association in Washington, D.C., concurred. “The high-dose vaccine increased security by about 15% total,” he informed MedPage Today in an interview.